Compare Alcon AG (ALC) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs CDW Corp. — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while CDW Corp. trades at $137.97 (market cap $17.79B). The key difference: Alcon AG is the larger of the two by market cap, and CDW Corp. pays the higher dividend (1.81%). Which is the better fit depends on your goals.
| ALC | CDW | |
|---|---|---|
Market Cap | $32.69B | $17.79B |
Sector | Health | Technology |
52-Week High | $92.22 | $182.18 |
52-Week Low | $62.02 | $99.30 |
Enterprise Value | $36.28B | $23.00B |
Dividend Yield | 0.54% | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
CDW trades at $139.23, up 4.39% today, near its consensus price target of $142.17. The stock shows a bullish technical trend with strong moving averages, while fundamentals reflect steady revenue of $22.42B in 2025 and robust profitability with a 44.16% ROE. Recent news highlights AI infrastructure demand fueling growth, and the company increased its share repurchase program by $1 billion in May 2026.
Outlook is positive with analyst consensus strongly bullish (70.59% buy ratings), though risks include margin pressure and competitive threats. The stock offers value with a P/E of 16.34 and growth potential from AI adoption, but investors should monitor execution on earnings targets and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
